BioNTech shares drop over 19% after Q4 earnings miss and co-founder exits

Financial outlets describe BioNTech’s 19% share price drop as a reaction to both a weak fourth quarter and a downbeat outlook as COVID-19 vaccine sales fade. This view holds that the departure of co-founders Uğur Şahin and Özlem Türeci adds uncertainty over BioNTech’s research pipeline and long-term growth. Commentators expect investors to demand clearer plans for oncology and other mRNA products before re-rating the stock.

• •BioNTech’s earnings miss and negative non-GAAP EPS show profits are under pressure as pandemic-era vaccine demand declines.
• •The company’s 2026 guidance for revenue and margins falls short of earlier market expectations.
• •The planned exit of co-founders Uğur Şahin and Özlem Türeci is seen as a risk to BioNTech’s innovation culture.
• •Institutional investors may shift funds toward other large vaccine or biotech names with more diversified product lines.
• •BioNTech will need to show concrete progress in cancer and other mRNA programs to rebuild confidence.